Module 6
Network Dynamics & Mitophagy
Note on terminology.“Fusion” and “fission” in this module refer to membrane events — two mitochondria merging their lipid bilayers into one, or a single mitochondrion dividing into two. This is notthe nuclear-physics meaning (atoms joining or splitting with release of binding energy). Mitochondrial dynamics is a cell-biology process driven by dynamin- family GTPases; no nuclear reactions are involved.
Mitochondria form dynamic networks that continually fuse, divide, move along microtubules, and are selectively degraded. The balance between these processes — mitochondrial network dynamics — controls ATP production, quality control, apoptosis susceptibility, and differentiation. Defects in the core machinery (MFN1/2, OPA1, DRP1, PINK1, Parkin) cause Charcot-Marie-Tooth, dominant optic atrophy, encephalopathies, and early-onset Parkinson’s disease.
1. The Fusion Machinery
Fusion couples two mitochondria into one by sequentially merging their outer and inner membranes. Three dynamin-family GTPases execute the process:
- MFN1 / MFN2 (mitofusin 1 and 2) on the outer membrane. Each is a large (86 kDa) GTPase with two transmembrane helices and a heptad-repeat coiled-coil domain. MFN1 on one mitochondrion trans-heterodimerises with MFN1 or MFN2 on the other via its HR2 coiled coil. GTP hydrolysis pulls the membranes together; membrane zippering follows. Cryo-EM (Nakamura 2022 Nat. Struct. Mol. Biol.) resolved the dimer architecture.
- OPA1 on the inner membrane. OPA1 is expressed as 8 isoforms, each cleaved by OMA1 and YME1L into long (L-OPA1) and short (S-OPA1) forms. Fusion requires both forms plus an inner-membrane proton gradient; OMA1 sensitively depolarises OPA1 under stress, switching it off. OPA1 also maintains cristae structure via its mitochondrial-contact-site role.
Disease: MFN2 mutations cause Charcot-Marie-Tooth disease type 2A (axonal neuropathy), demonstrating the specific requirement for long-range axonal mitochondrial transport and fusion. OPA1 mutations cause autosomal- dominant optic atrophy (DOA) — visual loss from retinal ganglion cell mitochondrial failure.
2. The Fission Machinery
Mitochondrial fission is executed by DRP1(dynamin-related protein 1), a soluble cytosolic GTPase recruited to the outer mitochondrial membrane by receptor proteins: Fis1, MFF (mitochondrial fission factor), MiD49, and MiD51. DRP1 oligomerises into helical filaments encircling the constriction site; GTP hydrolysis tightens the helix and severs both membranes simultaneously.
\[ \text{DRP1}_{cytosol} \;\xrightarrow{\text{MFF/Fis1}}\; \text{OMM} \;\xrightarrow{\text{GTP hydrolysis}}\; \text{membrane scission} \]
Fission sites are marked by the ER: tubules of the endoplasmic reticulum wrap around the mitochondrion and pre-constrict it to ~140 nm diameter before DRP1 recruitment (Friedman 2011 Science). Actin filaments nucleated by INF2 at these sites assist the pre-constriction.
DRP1 activity is modulated by post-translational modifications: CDK1 phosphorylation at S616 activates DRP1 during mitosis (ensuring daughter-cell mitochondrial inheritance); PKA phosphorylation at S637 inhibits DRP1 during fasting/starvation (promoting fusion and preserving network). Calcineurin dephosphorylates S637 during Ca2+ spikes, enabling stress-induced fragmentation. DRP1 loss-of-function mutations cause lethal encephalopathy.
Simulation: Steady-State Network Morphology
Monte-Carlo simulation of fusion/fission events on a population of discrete mitochondria. Balanced rates give a steady-state size distribution; fusion- dominant collapses the population into few large objects; fission-dominant produces many small fragments.
Click Run to execute the Python code
Code will be executed with Python 3 on the server
3. Axonal Transport & Miro/TRAK
Long neuronal axons (up to 1 m in humans) require continuous mitochondrial trafficking. Miro1/2 (RHOT1/2) is a Rho-family GTPase anchored in the outer mitochondrial membrane with two Ca2+-binding EF hands. It tethers mitochondria to TRAK1/2 adaptors, which in turn bind kinesin-1 (anterograde) and dynein (retrograde) motors for microtubule transport.
When a local Ca2+ spike (e.g., at a synaptic terminal) exceeds ~1 µM, Miro EF hands bind Ca2+ and release the motor, arresting the mitochondrion at the active site — matching ATP supply to demand. This calcium-gated arrest is central to synaptic plasticity and is disrupted in early PINK1/Parkin-linked Parkinson’s disease (Wang 2011 Cell).
4. Mitophagy: PINK1 / Parkin
Damaged mitochondria lose membrane potential (ΔΨm). In healthy mitochondria, the serine/threonine kinase PINK1 is imported via TOM/TIM, cleaved by matrix processing peptidase (MPP) and by inner- membrane protease PARL, and rapidly degraded by the proteasome. When ΔΨm drops, PINK1 import stalls; PINK1 accumulates on the outer membrane instead:
\[ \text{Healthy:} \ \text{PINK1} \xrightarrow{\text{TOM/TIM}} \text{matrix} \xrightarrow{\text{PARL/MPP}} \text{degraded} \]
\[ \Delta\Psi_m \downarrow \ \text{:}\ \text{PINK1 stabilised on OMM}\ \xrightarrow{\text{autophosphorylation}} \text{active kinase} \]
Active PINK1 phosphorylates ubiquitin at Ser65 and activates Parkin (an E3 ubiquitin ligase) by phosphorylating Parkin’s own ubiquitin-like domain. Activated Parkin synthesises K48- and K63-polyubiquitin chains on outer- membrane proteins (VDAC, MFN, MIRO, TOM20). These chains recruit the autophagy adaptors OPTN, NDP52, and p62, which anchor an LC3-decorated autophagosome. The whole damaged mitochondrion is engulfed and fused with a lysosome for degradation.
The process was first resolved by Narendra 2008 (J. Cell Biol.). PINK1 and Parkin mutations cause autosomal-recessive juvenile-onset Parkinson’s disease — the clearest monogenic link between mitochondrial quality control and neurodegeneration.
Simulation: PINK1/Parkin Cascade Timeline
Click Run to execute the Python code
Code will be executed with Python 3 on the server
5. Alternative Mitophagy Pathways
Beyond PINK1/Parkin, several receptor-mediated mitophagy pathways exist for specific physiological contexts:
- BNIP3 / NIX: outer-membrane receptors containing LIR motifs that bind LC3 directly. Essential for erythrocyte maturation (removal of all mitochondria) and for hypoxia-induced mitophagy.
- FUNDC1: OMM receptor dephosphorylated during hypoxia, exposing its LIR motif. Links hypoxic stress to mitophagy.
- Cardiolipin externalisation: oxidative damage flips cardiolipin from IMM to OMM, where LC3 binds it directly, targeting damaged mitochondria even without PINK1/Parkin.
- Mieap / Lonp1-mediated: matrix quality control degrading specific damaged proteins within the mitochondrion rather than the whole organelle.
6. Functional Consequences of the Dynamic Balance
The fusion/fission ratio sets mitochondrial network state, which determines cellular phenotype:
- Fused network: increased ATP output, tighter OXPHOS coupling, content mixing (mtDNA complementation, sharing of substrates), resistance to apoptosis. Dominant during G1-S cell cycle and nutrient abundance.
- Fragmented network: facilitates quality control (isolates damaged units for mitophagy), apoptosis (Bax/Bak pore formation at fission sites), distribution to daughter cells during mitosis. Dominant during stress and M phase.
Many kinases tune the balance: AMPK (starvation), CaMK (Ca2+signals), ERK1/2 (growth), CDK1 (mitosis). Together they make the mitochondrial network a dynamic sensor-effector of cellular metabolic state.
7. Therapeutic Targeting
Drugging mitochondrial dynamics is an emerging therapeutic area:
- Mdivi-1: small-molecule DRP1 inhibitor, preclinical in heart failure and neurodegeneration (off-target concerns limit clinical translation).
- P110: peptide inhibitor of DRP1-Fis1 interaction; protective in Parkinson’s and Alzheimer’s models (Qi 2013).
- Urolithin A (Amazentis): gut-microbiome-derived metabolite that induces mitophagy. Phase 2 trials in sarcopenia / aging (Andreux 2019 Nat. Metab.).
- UDCA (ursodeoxycholic acid): clinical trial for DOA (OPA1 mutations). Stabilises mitochondria, improves vision.
Key References
• Chan, D. C. (2006). “Mitochondria: dynamic organelles in disease, aging, and development.” Cell, 125, 1241–1252.
• Youle, R. J. & van der Bliek, A. M. (2012). “Mitochondrial fission, fusion, and stress.” Science, 337, 1062–1065.
• Nakamura, T. et al. (2022). “Cryo-EM structure of the human mitofusin 2 dimer.” Nat. Struct. Mol. Biol., 29, 555–562.
• Narendra, D. et al. (2008). “Parkin is recruited selectively to impaired mitochondria and promotes their autophagy.” J. Cell Biol., 183, 795–803.
• Pickrell, A. M. & Youle, R. J. (2015). “The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson’s disease.” Neuron, 85, 257–273.
• Friedman, J. R. et al. (2011). “ER tubules mark sites of mitochondrial division.” Science, 334, 358–362.
• Andreux, P. A. et al. (2019). “The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans.” Nat. Metab., 1, 595–603.
• Wang, X. et al. (2011). “PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility.” Cell, 147, 893–906.